NAPSRX CNPR EXAM (REVISED 18TH EDITION) 2025/26
QUESTIONS WITH DEFINITIVE VERIFIED ANSWERS
GUARANTEED PASS
What are some of the criteria that influence the decision to use
mass advertising in pharmaceutical marketing?
*the size of the target patient population
The chronicity of the disease state
The relevance of that disease state to its sufferers
The avg value of a patient taking medication
According to the AMA guidelines, who should accept subsidies
for continuing medical education conferences?
Conference sponsors
Who is the decision maker in pharmaceutical sales?
The physician
"fast track drugs" refer to
, Drugs approved for serious or life-threatening conditions
Rebate definition
The amount that the manufacturer of a drug pays to an insurer
or health plan for each unit of drug dispensed.
Generic drug definition
A drug identical to a brand-name drug in various aspects
How can e-prescribing prevent abuse of controlled
substances?
By cross-checking regional e-prescriptions
What the reason for increased cost and complexity of phase III
trials?
Patient recruitment
QUESTIONS WITH DEFINITIVE VERIFIED ANSWERS
GUARANTEED PASS
What are some of the criteria that influence the decision to use
mass advertising in pharmaceutical marketing?
*the size of the target patient population
The chronicity of the disease state
The relevance of that disease state to its sufferers
The avg value of a patient taking medication
According to the AMA guidelines, who should accept subsidies
for continuing medical education conferences?
Conference sponsors
Who is the decision maker in pharmaceutical sales?
The physician
"fast track drugs" refer to
, Drugs approved for serious or life-threatening conditions
Rebate definition
The amount that the manufacturer of a drug pays to an insurer
or health plan for each unit of drug dispensed.
Generic drug definition
A drug identical to a brand-name drug in various aspects
How can e-prescribing prevent abuse of controlled
substances?
By cross-checking regional e-prescriptions
What the reason for increased cost and complexity of phase III
trials?
Patient recruitment
